Discover 243 paid clinical trials in Syracuse, New York. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Syracuse is the medical research centre of central New York, and most of its trial activity runs through one institution: SUNY Upstate Medical University, the region's only academic medical centre and the largest employer in central New York. Cancer research leads the list, with ovarian cancer, lung cancer, and lymphoma studies recruiting through both cooperative groups such as the Alliance for Clinical Trials in Oncology and the National Cancer Institute and through industry sponsors, and migraine and Crohn's disease studies appear alongside them.
Filter
2
Filter results
Results: 243
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
for
Non-small Cell Lung Cancer
Location: Syracuse NY
Sponsor: State University of New York - Upstate Medical University
Sex: All
Age: 18+
Code: NCT02619448
Early_phase1, Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Sponsor: State University of New York - Upstate Medical University
Sex: All
Age: 18 - 55
Code: NCT06112093
Phase1, Recruiting
Apixaban or Enoxaparin After Head and Neck Cancer Surgery
for
Venous Thromboembolism, Head and Neck Cancer
Location: Syracuse NY
Sponsor: Kiranya Arnold
Sex: All
Age: 18 - 70+
Code: NCT07189897
Recruiting
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
for
Lupus Nephritis
Location: Syracuse NY, New York NY, San Antonio TX
Sponsor: Autolus Limited
Sex: All
Age: 12 - 65
Code: NCT07053800
Phase2, Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
for
Endometrial Cancer
Location: Syracuse NY, Toronto, New York NY, New Haven CT,
Sponsor: BioNTech SE
Sex: Female
Age: 18+
Code: NCT06340568
Phase3, Recruiting
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
for
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia